What is the brand name of the Measles (M), Mumps (M), and Rubella (R) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Brand Name of the MMR Vaccine

The brand name of the MMR (Measles, Mumps, Rubella) vaccine in the United States is M-M-R II, manufactured by Merck & Co., Inc. 1 Since June 2022, a second MMR vaccine called PRIORIX, manufactured by GlaxoSmithKline Biologicals, has also become available in the US market. 1

Available MMR Vaccine Products

M-M-R II (Merck & Co., Inc.)

  • Has been the sole MMR vaccine available in the United States since 1978 until 2022 1
  • Contains live attenuated measles (Enders-Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain) viruses 1
  • Administered as a subcutaneous injection 1

PRIORIX (GlaxoSmithKline Biologicals)

  • Approved by the FDA on June 6,2022 1
  • Contains three live attenuated viruses that are genetically similar or identical to the corresponding components in M-M-R II 1
  • Also administered as a subcutaneous injection 1

Interchangeability of the Vaccines

The Advisory Committee on Immunization Practices (ACIP) has determined that:

  • PRIORIX and M-M-R II are fully interchangeable for all indications 1
  • Either vaccine may be administered in any situation where an MMR virus-containing vaccine is indicated 1
  • Having two interchangeable vaccines from different manufacturers helps safeguard the US vaccine supply 1

Formulation Details

M-M-R II contains:

  • Approximately 0.3 milligrams of human albumin
  • 25 micrograms of neomycin
  • 14.5 milligrams of sorbitol
  • 14.5 milligrams of hydrolyzed gelatin 1

Prior to 2006, M-M-R II was manufactured using human serum albumin (HSA), but this was later replaced with recombinant human albumin (rHA) to mitigate potential supply risks. Studies have shown comparable immunogenicity and safety profiles between the two formulations. 2

Both M-M-R II and PRIORIX have demonstrated similar safety outcomes, including comparable rates of febrile convulsions, which are a rare but recognized adverse event following MMR vaccination. 3

The availability of both vaccines provides healthcare providers with options that can help ensure continued protection against these important vaccine-preventable diseases.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.